34 investment firms from six countries are already counted among over 130 participant companies already onboard, as well as pharma participants Merck, BMS, Shire, Teva, OSI and UCB. Our aim for BioTrinity 2010 is to again increase participation by a further 25% to 600-650 delegates over April 12-14 2010. The current rate of registration is about 2-fold higher than the previous year, strongly suggesting an even higher turnout in 2010 compared to 2009!